Journal
FRONTIERS IN ONCOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1174606
Keywords
ALK plus large B-cell lymphoma; TFG; ALK; ALK translocation; ALK fusion
Categories
Ask authors/readers for more resources
ALK+ LBCL is an aggressive and rare subtype of B-cell lymphoma. A unique case of ALK+ LBCL with a rare TFG::ALK fusion is reported, highlighting the need for larger genetic profiling studies. Deletions of FOXO1, PRKCA, and the MYB locus were also detected. This case report contributes to understanding the pathogenesis and potential therapeutic targets of this aggressive disease.
Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma (ALK+ LBCL) is an aggressive and rare subtype of B-cell lymphoma. Patients typically present with advanced clinical stage disease and do not respond to conventional chemotherapy; the median overall survival is 1.8 years. The genetic landscape of this entity remains poorly understood. Here we report a unique case of ALK+ LBCL harbouring a rare TFG::ALK fusion. Targeted next-generation sequencing showed no significant single nucleotide variants, insertions/deletions, or other structural variants beyond the TFG::ALK fusion; deep deletions of FOXO1, PRKCA, and the MYB locus were also detected. Our case report draws attention to this rare disease, highlights a need for larger genetic profiling studies, and focuses on the pathogenesis and potential therapeutic targets of this aggressive disease. To our knowledge, this is the first report of a TFG::ALK fusion in ALK+ LBCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available